












































































The nation’s spending for prescription drugs has grown dramatically in recent 
years (see Figure 1).  Even when controlling for general inflation, there has been a 
dramatic increase in drug spending, especially since the mid-1980s. 
A recent study by the Barents Group for the National Institute for Health Care 
Management (1999) attempted to measure the relative importance of different 
factors in the growth of drug spending. In general, the study split inflation into two 
categories: “utilization” effects and “price” effects. Each of these effects were further 
split between older drugs (drugs that entered the market before 1992) and new drugs 
(drugs that entered the market in 1992 or later).  
As Table 1 indicates, the study reported that increased utilization accounted for 
about one third of spending growth.
1  If price levels and the mix of prices had not 
changed between 1993 and 1998, 36 percent of the total spending growth would still have 
occurred as a result of the increased number of prescriptions. Increased utilization of 
newer drugs contributed almost twice as much as utilization of older drugs to this 
increase. 
The study found that about two thirds of spending growth from 1993 to 1998 was 
attributable to price. Of this portion, 22 percentage points were attributable to pure price 
increases for older drugs. Another 42 percentage points reflected the fact that newer 
drugs cost more than older drugs: the study estimated that the average 1998 price for 
drugs introduced in 1992 or later was $71.49 per prescription, compared to $30.47 for 
previously existing drugs. This difference reflects higher initial introduction prices as 
well as price increases after introduction.  
Thus the Barents study found that the replacement of older drugs by newer, more 
expensive, drugs was the single most important reason for rapidly increasing drug 
expenditure.  But as noted in Report to the President: Prescription Drug Coverage, 
Spending, Utilization, and Prices (Department of Health & Human Services, April 2000),   3 
the Barents study “did not attempt to measure how much of this difference [between new 
and old drug prices] reflects changes in quality as better, newer drugs replace older, less 
effective medications.”   
  This paper seeks to fill that gap, i.e. to provide evidence about differences in quality 
between new and old drugs (prescribed for given conditions).  We hypothesize that, in 
general, new drugs within a class or for a given diagnosis are of higher quality than old 
drugs, and that this increase may have a number of impacts, including reduced mortality, 
reduced morbidity, and reduced expenditure on other medical services, such as inpatient 
stays and emergency room visits 
  The hypothesis that drug quality is inversely related to drug age is consistent with 
“quality ladder” models of innovation.  Grossman and Helpman (1991, p. 84) describe 
the key features of these models
2: 
 
Technological progress stems from costly investments undertaken by profit-
seeking agents.  Entrepreneurs…attempt to develop superior versions of [goods 
that they see on the market].  When successful in the research lab, an innovator 
creates a new “state of the art” that captures market share at the expense of a 
previous generation product.  Growth will be sustained if commercial R&D 
remains an economically viable activity so that the average quality of industrial 
products continues to rise…Innovative goods are better than older products 
simply because they provide more “product services” in relation to their cost of 
production. 
 
If the quality of new drugs is higher than that of old drugs, the “quality-adjusted 
price” of new drugs may be lower than that of old drugs, even though the unadjusted 
price is higher.  Cutler et al (1996) found that the average cost of treating heart-attack 
patients increased from $11,175 in 1984 to $14,772 in 1991.  Most of this increase was 
due to a shift from older treatment regimens (medical management and catheterization) to 
                                                                                                
1 Part of this increase is due to the aging of the population: as Figure 2 shows, 
pharmaceutical consumption is strongly positively related to age, and the share of the 
population over the age of 65 increased from 8.1% in 1950 to 12.7% in 1997.   4 
newer, more expensive regimens (angioplasty and bypass surgery). While mean treatment 
cost increased at an average annual rate of 4.5%, life expectancy following a heart attack 
increased by 8 months—from 62 to 70 months—during this period.  Cutler et al showed 
that if the shift to newer treatment regimens were entirely responsible for the increase in 
life expectancy, and the value of a life-year is $25,000, then the shift actually reduced  
the “cost-of-living index”—a far more meaningful measure of inflation than the change 
in average treatment price—by 1.1% per year.   
In this paper, we will analyze prescribed medicine event-level data (linked to 
person- and condition-level data) from the 1996 Medical Expenditure Panel Survey 
(MEPS) to provide evidence about the effect of drug age—the number of years since the 
drug’s active ingredient was first approved by the FDA--on mortality, morbidity, and 
total medical expenditure, controlling for a number of characteristics of the individual 




To assess the effect that the age of the drug prescribed for a given condition has 
on mortality, morbidity, and total medical expenditures incurred to treat the condition, 
ideally one would like to randomly assign drugs of different ages to patients with that 
condition, and observe their outcomes and expenditures.  Unfortunately, I was unable to 
conduct a large-scale experiment in which drugs of different ages were randomly 
assigned to people.  Nevertheless, given the nature of the data-generating process and of 
the data available, I believe that a properly-specified model will enable me to make valid 
inferences about the effects of drug age. 
To evaluate the effect of drug quality, or age, on medical expenditure and 
outcomes, there must be a significant amount of exogenous, random variation in 
prescribing behavior.  The health economics literature suggests that, in general, medical 
practice variation is pervasive and sizeable.  If 10 doctors saw a patient with given set of 
symptoms, conditions, and characteristics, it is highly unlikely that they would prescribe 
the same medications for him.  Although practice variation may be undesirable from a 
                                                                                                
2  See also Aghion and Howitt (1990), Klette and Griliches (1997), and Segerstrom et al (1990).     5 
medical perspective, it is advantageous econometrically, since it facilitates identification 
of the effect of drug choice on the variables of interest.
3  
It would surely be a mistake, however, to think that all or perhaps even most of 
the variation in drugs prescribed for a given condition is random, i.e. uncorrelated with 
attributes of the individual and/or his condition that may influence outcomes and non-
drug medical expenditures.   If determinants of outcomes and non-drug expenditure are 
correlated with the age of the drug prescribed and we fail to control for them, we will 
obtain biased estimates of the effect of drug age on outcomes and expenditures.  For 
example, if more-educated people tend to receive newer drugs and (for unrelated reasons) 
also tend to have fewer hospital stays, if we don’t control for education we will 
overestimate the effect of drug age on hospital stays. 
  While omission of some variables (like education) is likely to result in 
overstatement of the effect of drug age on hospital stays, the omission of others seems 
likely to result in understatement of this effect.  Suppose that, among people with a given 
medical condition, the most severely ill are both more likely to receive the newest, most 
expensive, drugs and more likely to be hospitalized.  Failure to control for (untreated) 
severity of illness—which is difficult to do, in practice—would then bias the drug-age 
coefficient towards zero.  The net effect of plausible omitted-variables biases appears to 
be ambiguous, a priori. 
  Fortunately, the MEPS data enable us to control for many important attributes of 
the individual, condition, and prescription that influence outcomes and non-drug 
expenditures and that may be correlated with drug age.  These include sex, age, 
education, race, income, insurance status (whether the person is covered by private 
insurance, Medicare, and Medicaid), who paid for the drug, the condition for which the 
drug was prescribed, how long the person has had the condition, and the number of 
medical conditions reported by the person.  The first approach we will use to determine 
                                 
3 Significant geographical variation in treatment patterns was first documented by Wennberg and his 
colleagues (1982), who studied New England hospital markets.  Other investigators have corroborated this 
finding in many other settings.  For example, McPherson et al (1982) documented substantial variation in 
the use of common surgical procedures in New England, England, and Norway.  As Folland et al (2001, p. 
216) observe, “differences in treatment patterns across small areas may occur because of physicians’ 
uncertainty and ignorance over the best medical practice.”   6 
the ceteris paribus effect of drug age on outcomes and expenditure will be to include, in a 
very nonrestrictive fashion, all of these factors as covariates in models of the form: 
 
Yij = β  ln(AGE_DRUGij) + η  f(INCOMEj) + µ  MALEj + Σ h θ h CONDITIONijh + Σ y ψ y 
COND_DURijy + Σ k λ k RACEjk + Σ m φ m INSURANCEim + Σ n π n AGEin + Σ p γ p 




Yij = one of the following variables associated with the i
th prescription consumed by 
person j 
 
•  Mortality: whether person j died by the end of the survey period 
•  Morbidity indicators: whether person j missed work or school days or spent days in 
bed due to the condition for which prescription i was consumed 
•  The number of, and expenditure on, non-drug medical events, by type, associated 
with the condition (inpatient hospital stays, emergency-room visits, office-based 
visits, outpatient department visits, dental visits, home health visits, other medical 
expenditure events) 
 
AGE_DRUGi = the number of years prior to 1996 that the active ingredient in 
prescription i consumed by person j was first approved by the FDA 
 
INCOMEj = the income of the person consuming the prescription 
 
MALEj = 1 if the person consuming the prescription is male, otherwise zero 
 
CONDITIONijh = 1 if the i
th prescription consumed by person j is prescribed for 
condition (ICD9 3-digit diagnosis) h (h = 1, 2,…, 496), otherwise zero  
   7 
COND_DURijy = 1 if the condition for which the i
th prescription consumed by person j 
began y years ago, otherwise zero  
 
RACEjk = 1 if the person consuming the prescription is of race k (k = 1, 2,…,6), 
otherwise zero 
 
INSURANCEjm = 1 if the person consuming the prescription has health insurance status 
(e.g. private insurance, Medicare, Medicaid, no insurance) m, otherwise zero 
 
AGEjn = 1 if the person consuming the prescription is n years old (n = 0, 1, 2,…,99), 
otherwise zero 
 
EDUjp = 1 if the person consuming the prescription has p years of schooling (p = 0, 1, 
2,…,18), otherwise zero 
 
ε ij = the disturbance. 
 
While eq. (1) appears to control for many potentially relevant determinants of Y that may 
be correlated with AGE_DRUG, the fact that many individuals in the sample have both 
multiple medical conditions
4 and multiple prescriptions means that we can control for all 
individual characteristics—both observed and unobserved—by pursuing a second 
approach.  This involves estimating a model that includes “individual effects” (η j‘s):   
 
Yij = η j + β  ln(AGE_DRUGij) + Σ h θ h CONDITIONijh  
+ Σ y λ y COND_DURijy + Σ n π n + ε i           (2) 
 
                                 
4 Almost 2/3 of the people in the sample have 2 or more conditions.  Almost 95% of the 
conditions are experienced by people who have more than one condition.  Figure 3 shows 
the distribution of people in the MEPS sample, by number of reported medical 
conditions.   8 
Estimates of the parameter of interest (β ) from eq. (2) are based entirely on the within-
individual correlation between Y and AGE_DRUG, not on the between-individual 
correlation.
5  Suppose a person has two conditions, asthma and hypertension, and is 
taking medications for both.  He may have above-average numbers of hospital stays for 
both conditions, compared to other individuals with the same conditions.  And he may be 
taking older-than-average drugs for both conditions.  But due to the presence of 
individual effects in eq. (2), this would not make β  positive.  For β  to be positive, it 
would have to be the case that the condition for which the age of the person’s 
medications were more above average (relative to both individual and condition means) 




We will estimate equations (1) and (2) using data from the 1996 Medical 
Expenditure Panel Survey (MEPS), a nationally representative survey of health care use, 
expenditures, sources of payment, and insurance coverage for the U.S. civilian 
noninstitutionalized population. MEPS is co-sponsored by the Agency for Health Care 
Research and Quality and the National Center for Health Statistics. This survey is 
designed to yield comprehensive data that estimate the level and distribution of health 
care use and expenditures, monitor the dynamics of the health care delivery and insurance 
systems, and assess health care policy implications.
6 
The MEPS Household Component collects extremely detailed data from 22,061 
people on use and expenditures for office and hospital-based care, home health care, 
dental services, vision aids, and prescribed medicines. MEPS contains three kinds of data, 
i.e. data at three different levels of aggregation: the person level, the condition level (77 
thousand conditions), and the event level.  A person may have several conditions (e.g., 
hypertension, diabetes, and glaucoma); a given condition may be associated with a 
                                 
5 The η j‘s capture all attributes of the individual that do not vary across prescriptions and 
conditions, including sex, age, education, race, income, insurance status, and the number 
of medical conditions reported by the person.     9 
number of events.  Figure 4 indicates the linkages between events, conditions, and 
persons. Table 2 shows the number of events, by type, and their associated average 
expenditures.   
As indicated by eqs. (1) and (2), the unit of observation in our analysis is a 
prescribed-medicine event.  The MEPS Prescribed Medicine Event file contains 171,587 
observations.  The file reveals the amount paid for the prescription, by source of 
payment, and the National Drug Code, from which we determined (by linking to other 
pharmaceutical databases) the year in which the active ingredient was first approved by 
the FDA.  Figure 5 depicts the frequency distribution of MEPS prescriptions, by the date 
the active ingredient was first approved by the FDA.  About ¼ of prescriptions consumed 
were for drugs approved before 1950; more than half of the drugs consumed in 1996 
were approved before 1980.  Table 3 shows the drug classes with the largest number of 
prescriptions in 1996. 
Over 90% of the prescriptions are linked to exactly one medical condition.
7   The 
1996 Medical Conditions file contains summary information about these medical 
conditions, including: 
 
•  When the condition began 
•  Whether the person with the condition died by the end of the survey period 
•  Whether the person missed any work days due to the condition 
•  Whether the person missed any school days due to the condition 
•  Whether the person spent any days in bed due to the condition 
•  The number of home health events associated with the condition 
•  The number of dental events associated with the condition 
•  The number of hospital events associated with the condition 
•  The number of outpatient events associated with the condition 
•  The number of office-based events associated with the condition 
•  The number of emergency room events associated with the condition 
                                                                                                
6 For further information about the Medical Expenditure Panel Survey, see the web site: 
http://www.meps.ahrq.gov/.   10 
 
The Medical Conditions file does not report the amount of expenditure associated with 
each of these event types.  However expenditure (and charges) associated with each 
condition, by event type, can be computed from the records contained in the respective 
medical event files.
8   For example, one can compute total hospital expenditure associated 
with individual x’s hypertension.  In addition to calculating expenditure, by event type, 
we calculated total non-drug expenditure, i.e. the sum of expenditures on the six event 




Estimates of the parameter β  from equations (1) and (2) are presented in Table 4.   
We discuss first the estimates of β  from eq. (1), which controls for observed individual 
attributes such as age and education but excludes individual effects.  The first dependent 
variable we consider is the amount paid for the prescription.  The coefficient on 
ln(DRUG_AGE), β , is negative and highly significant, confirming the finding of previous 
studies (e.g. National Institute for Health Care Management Research and Educational 
Foundation (1999)) that new drugs are more expensive than old drugs prescribed for the 
same condition.  A unit decrease of ln(DRUG_AGE)—which would occur, for example, 
if a 15 year-old drug were replaced by a 5.5 year-old drug—would increase the cost of 
the prescription by about $18.   
The second dependent variable we consider is a mortality indicator: a dummy 
variable equal to 1 if the person had died by the end of round 3 of the survey, and 
otherwise equal to zero.  The mortality rate in this sample is quite low—only 0.28% (65) 
of the 23,230 persons died by the end of round 3.  This would seem to make it very 
difficult to detect any effect of drug age on mortality.  But recall that the unit of 
observation in our analysis is a prescription, not a person, and the fraction of observations 
in which mortality occurs is higher than 0.28%.  People with more prescriptions and more 
                                                                                                
7 5.3% are linked to more than one condition; 4.4% are not linked to any condition. 
8 The CLNK file contains the variables needed to link records in the MEPS 1996 event 
files to records in the MEPS 1996 condition file.    11 
conditions have a higher probability of death.  The fraction of conditions in which 
mortality occurs is almost twice as high—0.48% (371 out of 76,602). 
The estimates indicate that people consuming new drugs were significantly less 
likely to die by the end of round 3 than people consuming older drugs, controlling for all 
of the covariates included in eq. (1).  A unit decrease of ln(DRUG_AGE) is estimated to 
have decreased the probability of dying by 0.10 percentage points. 
  This finding is quite consistent with more aggregate (disease-level) evidence I 
presented in an earlier paper (Lichtenberg (2000)).  There I analyzed the relationship 
across diseases between the long-term reduction in life-years lost before age 75 and the 
relative utilization of new pharmaceutical products.  I found a highly significant positive 
relationship across diseases between the new drug share and mortality reduction in all 
three periods I analyzed.  Over 45 percent of the variation across diseases in the 1970-91 
reduction in mortality was explained by the new drug share.  Each new drug approved 
during the period 1970-91 was estimated to have saved 11,200 life-years in 1991. 
Next we consider morbidity indicators.  The fractions of conditions associated 
with any work-loss-, school-loss-, and bed-days, were as follows: 
 
Work-loss days  14.7 % 
School-loss days  9.0 % 
Bed days  14.0 %   12 
The coefficient on ln(DRUG_AGE) is insignificant in the school-loss days equation and 
only marginally significant in the bed-days equation.  But the estimates of the work-loss 
days equation indicate that people consuming new drugs were significantly less likely to 
experience work-loss days than people consuming old drugs.  This effect is highly 
statistically significant, but does not seem very large.  A unit decrease in 
ln(DRUG_AGE), which would increase the cost of the prescription by $18, would reduce 
the probability of any work-loss days by 0.0040.  If the increase in prescription cost were 
to be justified solely on the basis of reduced work-loss days, the average cost of work-
loss episodes would have to exceed $4500 (=$18/.0040).  However we have already 
found evidence of one other benefit of newer drugs—reduced mortality—and we have 
yet to consider another potential benefit: reduced expenditures on other medical inputs. 
We now present estimates of the effect of drug age on utilization of and 
expenditure on various non-drug medical events, by type.  The first event type we 
consider is hospital stays, the single most costly type, accounting for almost 42% of total 
medical expenditure.  The coefficient on ln(DRUG_AGE) in the equation explaining the 
number of hospital stays associated with the condition is positive and highly significant 
(t=3.68), indicating that people consuming new drugs had significantly fewer hospital 
stays than people consuming old drugs. A unit decrease in ln(DRUG_AGE) would 
reduce the expected number of hospital stays by .0059: replacing 1000 old prescriptions 
with 1000 new prescriptions—which would increase drug costs by $18,000--would 
reduce the number of hospital stays by 5.9.  Since average expenditure on a hospital stay 
is $7588, one might expect a reduction in hospital expenditure of $44,469 (=5.9 * 
$7588).  However the regression of a person’s actual hospital expenditures associated 
with a condition indicates an even larger reduction in hospital expenditure from the use of 
newer drugs: the implied hospital cost reduction is $55,824.  Use of newer drugs is 
evidently associated with less expensive (shorter), as well as fewer, hospital stays. 
  As before, this finding is quite consistent with more aggregate (disease-level) 
evidence I presented in an earlier paper (Lichtenberg (1996)).  In that paper I examined 
the effect of changes in the quantity and type of pharmaceuticals prescribed by physicians 
on rates of hospitalization, surgical procedure, mortality, and related variables.  The unit 
of analysis was a (ICD9 2-digit) disease or diagnosis, which we argued is analogous to a   13 
product (or industry) in industrial organization economics.  We controlled for the 
presence of "fixed (diagnosis) effects" by analyzing growth rates of the variables, using a 
database on diagnosis-level inputs and outcomes at two points in time (1980 and 1991 or 
1992).  Our principal findings were:  (1) The number of hospital stays, bed-days, and 
surgical procedures declined most rapidly for those diagnoses with the greatest increase 
in the total number of drugs prescribed and the greatest change in the distribution of 
drugs. The estimates imply that an increase of 100 prescriptions is associated with 1.48 
fewer hospital admissions, 16.3 fewer hospital days, and 3.36 fewer inpatient surgical 
procedures.  (2)  Greater quantity and novelty of pharmaceuticals had a negative impact 
on average length of stay in hospitals, as well as on the number of hospital stays.  (3) A 
$1 increase in pharmaceutical expenditure is associated with a $3.65 reduction in hospital 
care expenditure (ignoring any indirect cost of hospitalization).   
  The estimates indicate that reductions in drug age tend to reduce all types of non-
drug medical expenditure, although as the following table indicates, the reduction in 




reduction from unit 
decrease in 
ln(DRUG_AGE) 
% of total 
expenditure 
reduction 
Inpatient events  $55.82  78.5% 
Outpatient department events  $9.05  12.7% 
Office-based events  $3.11  4.4% 
Emergency room events  $2.63  3.7% 
Dental events  $0.47  0.7% 
Total $71.09  100.0% 
The total estimated reduction in non-drug expenditure from a unit decrease in 
ln(DRUG_AGE) is $71.09.  This reduction in non-drug expenditure is much greater than 
the increase in prescription cost ($18.00), so reducing the age of the drug results in a 
substantial net reduction in the total cost of treating the condition.   
  The estimates in the second column of Table , which are based on models that 
include individual effects, are quite similar, broadly speaking, to the estimates in the first   14 
column, which are based on models without individual effects.
9  They also suggest that 
people consuming new drugs were significantly less likely to experience work-loss days 
than people consuming old drugs, although the estimated effect is about 30% smaller.  
The estimated effect of ln(DRUG_AGE) on total non-drug expenditure to treat the 
condition is almost identical--$72.22—but the distribution of cost reduction by event type 
is somewhat different.  When individual effects are included, the reduction in inpatient 
expenditure accounts for an even higher proportion (89%) of the total reduction in non-
drug expenditures.   
  To summarize, estimates of both eq. (1), which controls for many observed 
characteristics of the person, condition, and prescription, and eq, (2), which controls for 
all individual attributes (both observed and unobserved), indicate that people taking 
newer drugs are likely to have significantly lower medical expenditures and have fewer 
work-loss days than people taking older drugs for the same condition.  The first equation 
also indicates that mortality is lower among people taking newer drugs. 
  It is sometimes suggested that, because generic drugs tend to be less expensive 
than branded drugs, allowing people to use only generic drugs might be an effective 
means of reducing health expenditure.  As the following table shows, generic drugs tend 
to be much older than branded drugs.   
 
  % of 
prescriptions 
mean age (in 
years) in 1996 
Branded drugs  60.0% 23 
Generic drugs  40.0% 38 
All drugs  100.0% 29 
 
Suppose that, instead of consuming the actual mix of 60% branded and 40% generic 
drugs, people had to consume only generic drugs.  This would increase the mean age of 
drugs consumed by 31%, from 29 years to 38 years.  Our estimates indicate that denying 
                                 
9 Unlike the morbidity and expenditure variables, the mortality variable does not exhibit any within-
individual variation—the cause of death is not indicated—so we are unable to estimate the mortality 
equation with individual effects.   15 
people access to branded drugs would increase total treatment costs, not reduce them, 




The nation’s spending for prescription drugs has grown dramatically in recent years.  
Previous studies have shown that the replacement of older drugs by newer, more 
expensive, drugs is the single most important reason for this increase, but they did not  
attempt to measure how much of the difference between new and old drug prices reflects 
changes in quality as better, newer drugs replace older, less effective medications.  
 In this paper, we analyzed prescribed medicine event-level data (linked to 
person- and condition-level data) from the 1996 Medical Expenditure Panel Survey 
(MEPS) to provide evidence about the effect of drug age on mortality, morbidity, and 
total medical expenditure, controlling for a number of characteristics of the individual 
and the event.  (Previous researchers have hypothesized that differences in treatment 
patterns across individuals and areas may occur because of physicians’ uncertainty and 
ignorance over the best medical practice.)  The MEPS data enable us to control for many 
important attributes of the individual, condition, and prescription that influence outcomes 
and non-drug expenditures and that may be correlated with drug age.  These include sex, 
age, education, race, income, insurance status, who paid for the drug, the condition for 
which the drug was prescribed, how long the person has had the condition, and the 
number of medical conditions reported by the person.  Indeed, the fact that many 
individuals in the sample have both multiple medical conditions and multiple 
prescriptions means that we can control for all individual characteristics—both observed 
and unobserved—by including “individual effects”. 
  The results provide strong support for the hypothesis that the replacement of older 
by newer drugs results in reductions in mortality, morbidity, and total medical 
expenditure. Although the mortality rate in this sample is quite low—making it difficult 
to detect any effect of drug age on mortality—we found that people consuming new 
drugs were significantly less likely to die by the end of the survey than people consuming 
older drugs.  As to morbidity, we found that people consuming new drugs were   16 
significantly less likely to experience work-loss days than people consuming old drugs, 
although the estimated effect was not very large. 
  The estimates indicated that reductions in drug age tend to reduce all types of 
non-drug medical expenditure, although the reduction in inpatient expenditure is by far 
the largest.  The total estimated reduction in non-drug expenditure from reducing the age 
of the drug is almost four times as large as the increase in drug expenditure, so reducing 
the age of the drug results in a substantial net reduction in the total cost of treating the 
condition.   
It is sometimes suggested that, because generic drugs tend to be less expensive 
than branded drugs, allowing people to use only generic drugs might be an effective 
means of reducing health expenditure.  However generic drugs tend to be much older 
than branded drugs, and our estimates indicate that denying people access to branded 
drugs would increase total treatment costs, not reduce them, and would lead to worse 
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1977Percent of rise in drug 
spending attributable to 
prices (at introduction and 
subsequent increases)
Percent of rise in drug 
spending attributable to 
utilization
Total
New drugs (1992 or later) 42% 23% 65%
Older drugs 22% 13% 35%
Total 64% 36% 100%
Report to the President: Prescription Drug Coverage, Spending, Utilization, and Prices
Department of Health & Human Services, April 2000
http://aspe.hhs.gov/health/reports/drugstudy/index.htm
                                                       
Percentage Contribution of Changes in Price and Utilization to 1993-98 
Increase in Prescription Drug Spending
Source: National Institute for Health Care Management Research and Educational Foundation, 































































Cumulative % of peoplePrescribed medicine events
Office-based visit events
Inpatient visit events
Condition 1 Outpatient visit events
Dental visit events
Emergency room visit events





Condition 2 Outpatient visit events
Dental visit events
Emergency room visit events




Person 2 Condition 1 Outpatient visit events
Dental visit events
Emergency room visit events
Other medical expenditure events
Figure 4







% of total 
expenditure
Inpatient visit events 2,207 $7,587.60  $16,745,833  41.5%
Office-based visit events 100,320 $81.45  $8,170,815  20.2%
Prescribed medicine events 171,587 $32.77  $5,623,511  13.9%
Outpatient visit events 9,957 $412.55  $4,107,802  10.2%
Dental visit events 22,165 $142.92  $3,167,747  7.8%
Emergency room visit events 3,899 $345.34  $1,346,490  3.3%
Other medical expenditure events 6,402 $189.70  $1,214,484  3.0%
All 316,537 $40,376,682 100.0%
Table 2
Frequency of and expenditure on MEPS eventsFigure 5
Frequency distribution of MEPS prescriptions, 































sMillions of Rx's % of Rx's Drug class
83.0 5.1% calcium channel blocking agents
77.7 4.8% upper respiratory combinations
73.8 4.6% nonsteroidal anti-inflammatory agents
66.4 4.1% aminopenicillins
63.2 3.9% narcotic analgesic combinations
60.6 3.7% angiotensin converting enzyme inhibitors
52.5 3.2% estrogens
41.2 2.5% thyroid drugs
41.1 2.5% SSRI antidepressants
39.7 2.4% beta-adrenergic blocking agents
37.6 2.3% macrolides
35.1 2.2% H2 antagonists
34.1 2.1% sulfonylureas
32.9 2.0% adrenal cortical steroids
31.8 2.0% loop diuretics
31.1 1.9% HMG-CoA reductase inhibitors
30.5 1.9% minerals and electrolytes
29.9 1.8% insulin
29.6 1.8% topical anti-infectives
24.8 1.5% topical steroids
24.4 1.5% antihistamines
22.8 1.4% antianginal agents
21.6 1.3% inotropic agents
20.1 1.2% second generation cephalosporins
19.8 1.2% respiratory inhalant products
19.1 1.2% natural penicillins
18.6 1.1% benzodiazepines
18.1 1.1% nasal steroids
16.3 1.0% miscellaneous antipsychotic agents
16.3 1.0% progestins
Note: Only those drug classes accounting for at least 1% of total prescriptions are 
shown
Table 3
Drug classes with the largest number of prescriptions in 1996Dependent variable Eq. (1) Eq. (2)




(=1 if person died by the end of round 3) (2.76)
Morbidity
MISSED WORK DAYS dummy 0.0040 0.0028
(=1 if person missed any work days due to the condition) (3.32) (3.25)
MISSED SCHOOL DAYS dummy 0.0001 -0.0005
(=1 if person missed any school days due to the condition) (0.21) (1.28)
BED DAYS dummy 0.0023 0.0019
(=1 if person spent any days in bed due to the condition) (1.55) (1.60)
Non-drug events
Number of hospital stays associated with condition 0.0059 0.0043
(8.04) (6.34)
Hospital expenditure associated with condition 55.82 63.95
(3.69) (3.81)
Number of outpatient dept. visits associated with condition 0.0034 0.0001
(5.46) (0.19)
Outpatient dept. expenditure associated with condition 9.05 4.91
(9.66) (5.42)
Number of office visits associated with condition -0.0054 -0.0031
(1.97) (1.18)
Office visit expenditure associated with condition 3.11 1.78
(4.72) (2.97)
Number of emergency room visits associated with condition 0.0073 0.0028
(11.58) (5.08)
Emergency room expenditure associated with condition 2.63 1.21
(5.90) (3.02)
Number of dental visits associated with condition 0.0034 0.0028
(5.53) (5.04)
Dental expenditure associated with condition 0.4730 0.3727
(1.44) (1.40)
Total non-drug expenditure associated with condition 71.09 72.22
(4.69) (4.29)
Table 4
Estimates of b b (the coefficient on ln(DRUG_AGE)) from eqs. (1)  and (2)
(t-statistics in parentheses)